Rs3802278 in 3’-UTR of SULF1 associated with platinum resistance and survival in Chinese epithelial ovarian cancer patients

References

• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502–16.
   PubMed Web of Science ®Google Scholar
• Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, Ambrosone CB, et al. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122(1):121–6.
   PubMed Web of Science ®Google Scholar
• Christie EL, Bowtell DDL. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii13–viii15.
   PubMedGoogle Scholar
• Yang JD, Sun Z, Hu C, Lai J, Dove R, Nakamura I, et al. Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. Genes Chromosom Cancer. 2011;50(2):122–35.
   PubMed Web of Science ®Google Scholar
• Uchimura K. Sulfs: extracellular endosulfatases that regulate physiological functions of heparan sulfate. Seikagaku. 2011;83(3):216–23.
   PubMedGoogle Scholar
• Hammond E, et al. The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics. Front Oncol. 2014; 4:195.
   PubMedGoogle Scholar
• Kalus I, Rohn S, Puvirajesinghe TM, Guimond SE, Eyckerman-Kölln PJ, ten Dam G, et al. Sulf1 and Sulf2 differentially modulate heparan sulfate proteoglycan sulfation during postnatal cerebellum development: evidence for neuroprotective and neurite outgrowth promoting functions. PLoS One. 2015;10(10):e0139853.
   PubMed Web of Science ®Google Scholar
• Tao Y, Han T, Zhang T, Sun C. Sulfatase-2 promotes the growth and metastasis of colorectal cancer by activating Akt and Erk1/2 pathways. Biomed Pharmacother. 2017;89:1370–7.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran R, Nakamura I, Hu C, Chen G, Oseini AM, Seven ES, et al. Activation of the transforming growth factor-beta/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma. Hepatology. 2015;61(4):1269–83.
   PubMed Web of Science ®Google Scholar
• Liu C-T, Zhu S-T, Li P, Wang Y-J, Zhang H, Zhang S-T. SULF1 inhibits proliferation and invasion of esophageal squamous cell carcinoma cells by decreasing heparin-binding growth factor signaling. Dig Dis Sci. 2013;58(5):1256–63.
   PubMed Web of Science ®Google Scholar
• Xu G, Ji W, Su Y, Xu Y, Yan Y, Shen S, et al. Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model. Oncotarget. 2014;5(13):5029–39.
   PubMedGoogle Scholar
• Yi B, Qiu Y, Ji W, Wei M, Liu C, Peng Z, et al. Desulfation of cell surface HSPG is an effective strategy for the treatment of gallbladder carcinoma. Cancer Lett. 2016; 381(2) :349–58.
   PubMed Web of Science ®Google Scholar
• Lai J-P, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, et al. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene. 2004;23(7):1439–47.
   PubMed Web of Science ®Google Scholar
• Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, et al. Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene. 2007;26(34):4969–78.
   PubMed Web of Science ®Google Scholar
• Wichert A, Stege A, Midorikawa Y, Holm PS, Lage H. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Oncogene. 2004;23(4):945–55.
   PubMed Web of Science ®Google Scholar
• Lanzi C, Zaffaroni N, Cassinelli G. Targeting heparan sulfate proteoglycans and their modifying enzymes to enhance anticancer chemotherapy efficacy and overcome drug resistance. Curr Med Chem. 2017;24(26):2860–86.
   PubMed Web of Science ®Google Scholar
• Qianying Ouyang YL, Tan J, Li J, Yang D, Zeng F, Huang W, et al. Loss of ZNF587B and SULF1 contributed to cisplatin resistance in ovarian cancer cell lines based on Genome-scale CRISPR/Cas9 screening. Am J Cancer Res. 2019;9(5):988–98.
   PubMed Web of Science ®Google Scholar
• Li T, Peng J, Zeng F, Zhang K, Liu J, Li X, et al. Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer. CP. 2017;55(10):774–80.
   Google Scholar
• Dardiotis E, Siokas V, Garas A, Paraskevaidis E, Kyrgiou M, Xiromerisiou G, et al. Genetic variations in the SULF1 gene alter the risk of cervical cancer and precancerous lesions. Oncol Lett. 2018;16(3):3833–41.
   PubMed Web of Science ®Google Scholar
• Zhou Q, et al. Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study. Onco Targets Ther. 2016;9:2749–57.
   PubMed Web of Science ®Google Scholar
• Okolicsanyi RK, Faure M, Jacinto JME, Chacon-Cortes D, Chambers S, Youl PH, et al. Association of the SNP rs2623047 in the HSPG modification enzyme SULF1 with an Australian Caucasian breast cancer cohort. Gene. 2014;547(1):50–4.
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2(1):16061.
   PubMed Web of Science ®Google Scholar
• Canaz E, Grabowski JP, Richter R, Braicu EI, Chekerov R, Sehouli J. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: an analysis of five prospective phase II/III trials of NOGGO metadata base. Gynecol Oncol. 2019;154(3):539–46.
   PubMed Web of Science ®Google Scholar
• Ren T, Sun T-T, Wang S, Sun J, Xiang Y, Shen K, et al. Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer. J Ovarian Res. 2018;11(1):40.
   PubMedGoogle Scholar
• Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem. 2003; 278(25) :23107–17.
   PubMed Web of Science ®Google Scholar
• Lai J-P, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology. 2004;126(1):231–48.
   PubMed Web of Science ®Google Scholar